Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01090622 | Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) | PHASE1 | COMPLETED | 4 | — | — | Apr 1, 2010 | Sep 1, 2010 | Mar 16, 2012 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| Matching Placebo | PLACEBO_COMPARATOR | - |
| XPF-001 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| XPF-001 | DRUG | Oral capsule |
| Placebo | DRUG | Oral capsule |
Inclusion Criteria: The study requires you to: * Be18-75 years old * Have inherited erythromelalgia * Be experiencing pain caused by erythromelalgia (Moderate pain score 4/10) * Be generally healthy (apart from your pain) * Stop taking your usual pain medications for 9 days * Not be pregnant or br...